[go: up one dir, main page]

WO2003028661A3 - Compositions de meningocoque assorties d'un adjuvant - Google Patents

Compositions de meningocoque assorties d'un adjuvant Download PDF

Info

Publication number
WO2003028661A3
WO2003028661A3 PCT/US2002/031726 US0231726W WO03028661A3 WO 2003028661 A3 WO2003028661 A3 WO 2003028661A3 US 0231726 W US0231726 W US 0231726W WO 03028661 A3 WO03028661 A3 WO 03028661A3
Authority
WO
WIPO (PCT)
Prior art keywords
meningococcus
adjuvanted
compositions
neisserial
cpg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/031726
Other languages
English (en)
Other versions
WO2003028661A2 (fr
Inventor
Derek O'hagan
Nicholas Valiante
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/010869 external-priority patent/WO2002080648A2/fr
Priority to AU2002334844A priority Critical patent/AU2002334844B2/en
Priority to MXPA04003186A priority patent/MXPA04003186A/es
Priority to JP2003531997A priority patent/JP4522699B2/ja
Priority to EP02800481A priority patent/EP1438323A4/fr
Priority to CA2462646A priority patent/CA2462646C/fr
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to NZ532274A priority patent/NZ532274A/en
Priority to BR0213119-6A priority patent/BR0213119A/pt
Publication of WO2003028661A2 publication Critical patent/WO2003028661A2/fr
Publication of WO2003028661A3 publication Critical patent/WO2003028661A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

L'invention concerne une combinaison d'oligonucléotides CpG et de microparticules polymères qui constitue un adjuvant extrêmement efficace pour des antigènes de Neisseria. L'invention concerne donc une composition comprenant (a) un antigène de Neisseria; (b) un oligonucléotide CpG; et (c) une microparticule polymère biodégradable.
PCT/US2002/031726 2001-10-03 2002-10-03 Compositions de meningocoque assorties d'un adjuvant Ceased WO2003028661A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BR0213119-6A BR0213119A (pt) 2001-10-03 2002-10-03 Composição imunogênica e uso da mesma
MXPA04003186A MXPA04003186A (es) 2001-10-03 2002-10-03 Composiciones de meningococo coadyuvantes.
JP2003531997A JP4522699B2 (ja) 2001-10-03 2002-10-03 アジュバント化されたＭｅｎｉｎｇｏｃｏｃｃｕｓ組成物
EP02800481A EP1438323A4 (fr) 2001-10-03 2002-10-03 Compositions de meningocoque assorties d'un adjuvant
CA2462646A CA2462646C (fr) 2001-10-03 2002-10-03 Compositions de meningocoque assorties d'un adjuvant
AU2002334844A AU2002334844B2 (en) 2001-10-03 2002-10-03 Adjuvanted meningococcus compositions
NZ532274A NZ532274A (en) 2001-10-03 2002-10-03 Adjuvanted meningococcus compositions

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US32692901P 2001-10-03 2001-10-03
US60/326,929 2001-10-03
USPCT/US02/10869 2002-04-05
PCT/US2002/010869 WO2002080648A2 (fr) 2001-04-05 2002-04-05 Augmentation de l'immunite des muqueuses a la suite d'un amorçage parenteral
US37354702P 2002-04-17 2002-04-17
US60/373,547 2002-04-17
US38067702P 2002-05-13 2002-05-13
US60/380,677 2002-05-13
US25443802A 2002-09-24 2002-09-24
US0230423 2002-09-24
USPCT/US02/30423 2002-09-24
US10/254,438 2002-09-24

Publications (2)

Publication Number Publication Date
WO2003028661A2 WO2003028661A2 (fr) 2003-04-10
WO2003028661A3 true WO2003028661A3 (fr) 2003-10-09

Family

ID=32601151

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/031726 Ceased WO2003028661A2 (fr) 2001-10-03 2002-10-03 Compositions de meningocoque assorties d'un adjuvant

Country Status (8)

Country Link
EP (1) EP1438323A4 (fr)
JP (1) JP4522699B2 (fr)
CN (1) CN100354297C (fr)
AU (1) AU2002334844B2 (fr)
BR (1) BR0213119A (fr)
CA (1) CA2462646C (fr)
NZ (1) NZ532274A (fr)
WO (1) WO2003028661A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
AU2003260357B2 (en) * 2002-08-02 2009-10-29 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from lgtB- Neisseria minigitidis
WO2004060396A2 (fr) 2002-12-27 2004-07-22 Chiron Corporation Immunogenes contenant des compositions de phospholipide
DE602004020189D1 (de) * 2003-01-30 2009-05-07 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
CN102319427A (zh) * 2003-01-30 2012-01-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
ES2328697T5 (es) 2003-06-02 2017-07-25 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunogénicas basadas en micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
JP2007523173A (ja) * 2004-02-20 2007-08-16 イデラ ファーマシューティカルズ インコーポレイテッド 修飾免疫調節オリゴヌクレオチドにより誘導された強力な粘膜免疫応答
US9107813B2 (en) 2004-11-15 2015-08-18 Derek T. O'Hagan Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant
CN107261127A (zh) 2005-01-28 2017-10-20 盖伦生物公司 免疫活性组合物
US20080138431A1 (en) * 2005-03-02 2008-06-12 James Edward Eyles Pharmaceutical Composition
ES2664753T3 (es) 2007-12-07 2018-04-23 Glaxosmithkline Biologicals Sa Composiciones de inducción de respuestas inmunes
CN101559225B (zh) * 2008-04-18 2012-07-11 北京生物制品研究所 脑膜炎球菌疫苗
KR102283760B1 (ko) * 2012-06-21 2021-08-03 노쓰웨스턴유니버시티 펩티드 접합된 입자

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050075A2 (fr) * 1999-02-26 2000-08-31 Chiron S.P.A. Developpement de l'activite bactericide des antigenes de neisseria a l'aide d'oligonucleotides a motifs cg
WO2000050006A2 (fr) * 1999-02-26 2000-08-31 Chiron Corporation Microemulsions a macromolecules et microparticules adsorbees
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69841807D1 (de) * 1997-11-06 2010-09-16 Novartis Vaccines & Diagnostic Neisseriale antigene
ES2333071T5 (es) * 1998-01-14 2015-08-17 Novartis Vaccines And Diagnostics S.R.L. Antígenos de Neisseria meningitidis
MX343744B (es) * 1998-05-01 2016-11-22 J Craig Venter Inst Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
DK1100468T3 (da) * 1998-07-29 2006-07-31 Chiron Corp Mikropartikler med adsorbent-overflader, fremgangsmåder til fremstilling af disse samt anvendelser deraf
EP1559795A3 (fr) * 1998-10-09 2005-11-09 Chiron Corporation Sequences genomiques de neisseria et methode pour leur utilisation
PT1228217E (pt) * 1999-04-30 2013-01-28 Novartis Vaccines & Diagnostic Antígenos de neisseria conservados
AU3948801A (en) * 2000-02-28 2001-09-12 Chiron Spa Heterologous expression of neisserial proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO2000050075A2 (fr) * 1999-02-26 2000-08-31 Chiron S.P.A. Developpement de l'activite bactericide des antigenes de neisseria a l'aide d'oligonucleotides a motifs cg
WO2000050006A2 (fr) * 1999-02-26 2000-08-31 Chiron Corporation Microemulsions a macromolecules et microparticules adsorbees

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1438323A4 *

Also Published As

Publication number Publication date
EP1438323A4 (fr) 2007-08-01
CA2462646A1 (fr) 2003-04-10
CA2462646C (fr) 2013-02-12
JP4522699B2 (ja) 2010-08-11
BR0213119A (pt) 2004-12-28
CN1599746A (zh) 2005-03-23
NZ532274A (en) 2006-02-24
EP1438323A2 (fr) 2004-07-21
WO2003028661A2 (fr) 2003-04-10
AU2002334844B2 (en) 2007-08-02
CN100354297C (zh) 2007-12-12
JP2005526697A (ja) 2005-09-08
AU2002334844B8 (en) 2003-04-14

Similar Documents

Publication Publication Date Title
WO2003028661A3 (fr) Compositions de meningocoque assorties d'un adjuvant
WO2000050075A3 (fr) Developpement de l'activite bactericide des antigenes de neisseria a l'aide d'oligonucleotides a motifs cg
WO2003051392A3 (fr) Vaccin
AU2002301801A1 (en) Cosmetic compositions containing an aminosilicone and a conditioner, and uses thereof
DE60210456D1 (de) Solubisierung von kapseln polysacchariden
AU2001297522A1 (en) Heat curable silicone compositions
GB9817052D0 (en) Vaccine
WO2002102305A3 (fr) Composition d'adjuvant pour vaccins administres par les muqueuses ou par injection
UY26555A1 (es) Composición farmacéutica para modulación inmunológica y preparación de vacunas
WO2004075829A3 (fr) Vaccin contre la grippe contenant un adjuvant
AU2002307971A1 (en) Vaccine against the nile fever virus
WO2007013893A3 (fr) Compositions immunogenes contenant un antigene de l'anthrax, des microparticules de polymeres biodegradables, et un adjuvant immunologique contenant un polynucleotide
AU2001288953A1 (en) Novel polymers and photoresist compositions comprising labile polymers backbonesfor short wave imaging
ZA200209048B (en) Cosmetic compositions containing an aminosilicone and an insoluble conditioner, and uses thereof.
WO2007034166A8 (fr) Vaccin a adjuvant
WO1999052523A3 (fr) Compositions de flutamide et leurs preparations
AR042595A1 (es) Composiciones de meningococos con adyuvante
AU2003225057A1 (en) Polymer compositions that stabilize and control the release of formaldehyde-treated vaccine antigens
AU2002325783A1 (en) Vaccine formulation potentiated by the combination of a DNA and an antigen
WO2001049320A3 (fr) Compositions pharmaceutiques et leur preparation
ZA200303826B (en) Immunoprotective recombinent antigen from Anaplasma marginale, vaccine compositions and methods of use.
AU2002317056A1 (en) Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres
AU2002365205A1 (en) Brucellosis vaccine composition comprising poly($g(e)-caprolactone) microparticles as an adjuvant
AU2002315073A1 (en) Triggered release from proteinoid microspheres
CA2452008A1 (fr) Ltb4 comme adjuvant de vaccin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WPC Withdrawal of priority claims after completion of the technical preparations for international publication
WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/003186

Country of ref document: MX

Ref document number: 2462646

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003531997

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 532274

Country of ref document: NZ

Ref document number: 2002334844

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002800481

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20028241282

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002800481

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 532274

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002334844

Country of ref document: AU